Pfizer-J&J Legal Brawl Could Set Precedent For Competition In Biosimilar Landscape

If Pfizer is successful, it could discourage brand name companies from using deals with insurers to limit competition in the emerging biosimilar market. If Pfizer loses, the case could highlight a strategy those companies could continue to use to deter competition.<img alt="" border="0" src="http://pixel.wp.com/b.gif?host=khn.org&blog=7618883&post=770118&subd=kaiserhealthnews&ref=&feed=1" width="1" height="1" />